Just weeks away from reporting key endpoint data from a Phase III trial of its lead therapy, Relypsa has mapped out plans to go public, shooting for a $126.5 million payday to help complete a prospective transformative leap into marketing.
Rockwell Medical shares surged early today after the biotech announced that its second, duplicate Phase III study for a new iron-delivery drug hit its primary and secondary endpoints, setting the stage for a new drug application.
AstraZeneca CEO Pascal Soriot has taken another step forward in his turnaround campaign, committing $350 million in cash and up to $465 million in milestones to partner up with FibroGen as it positions a lead anemia drug for late-stage trials.
Takeda Pharmaceuticals and Affymax ($AFFY) have sewn up another supply deal for their anemia drug Omontys. DSI Renal, one of the largest dialysis providers in the U.S., agreed to adopt Omontys to treat their patients with chronic kidney disease.
Malformed kidneys in newborn babies could be markers for mental illness and problems with behavior and understanding.
Under the new partnership, Adelyx gets $35 million up front, plus up to $237.5 million in milestones, provided the RX5791 drug makes it to market.
A deal-hungry AstraZeneca has bagged a Phase IIb-ready compound for chronic kidney disease in a $272 million deal with Fremont, CA-based Ardelyx. The pharma giant agreed to pay $35 million upfront to partner on Ardelyx's lead drug, RDX5791, which spurs the body to bypass vulnerable kidneys when it flushes sodium.
Vascular Pharmaceuticals has nailed down $16 million in a Series A round of financing while revealing a deal that gives a unit of Johnson & Johnson an option to acquire the biotech, the company announced Wednesday. The injection of capital fuels the University of North Carolina (UNC) spinoff's efforts to advance its lead experimental drug to initial human studies as a new treatment for diabetic kidney disease.
A biomarker emerging from European research has potential to select out those patients who don't need immunosuppressive treatment for an autoimmune kidney disorder, and therefore could avoid exposure to unnecessary side effects.
In the latest in a string of biotech acquisitions, Amgen says it is buying KAI Pharmaceuticals for $315 million in cash.